Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Pegilodecakin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    UCB To Share BIMZELX Two-Year Data In Arthritis At EULAR 2024
    UCB To Share BIMZELX Two-Year Data In Arthritis At EULAR 2024

    12 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ucb-to-share-first-presentations-of-bimzelx-bimekizumab-bkzx-two-year-data-in-axial-spondyloarthritis-and-psoriatic-arthritis-at-eular-2024-302170292.html

    PR NEWSWIRE
    12 Jun 2024
    Share Share
    Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102
    Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102

    22 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/22/2502147/0/en/Cue-Biopharma-Doses-First-Patient-in-Phase-1-Study-of-CUE-102-for-Wilms-Tumor-1-WT1-expressing-cancers.html

    GLOBENEWSWIRE
    22 Aug 2022
    Share Share
    NeoImmuneTech Begins Dosing in Phase 1b Study of NT-I7 and Kymriah in r/rLBCL
    NeoImmuneTech Begins Dosing in Phase 1b Study of NT-I7 and Kymriah in r/rLBCL

    13 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211013005218/en

    BUSINESSWIRE
    13 Oct 2021
    Share Share
    Calypso Biotech Announces First Patient dosed with CALY-002
    Calypso Biotech Announces First Patient dosed with CALY-002

    09 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210908006073/en/Calypso-Biotech-Announces-First-Patient-With-Celiac-Disease-Dosed-in-anti-Interleukin-15-IL-15-Monoclonal-Antibody-CALY-002-Phase-1b-Trial-and-Extension-of-Series-A-to-%E2%82%AC28M

    BUSINESSWIRE
    09 Sep 2021
    Share Share
    Selecta & Cyrus Biotech. Collaborate for Novel Engineered Therapeutic Proteins
    Selecta & Cyrus Biotech. Collaborate for Novel Engineered Therapeutic Proteins

    08 Sep 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/09/08/2293345/0/en/Selecta-Biosciences-and-Cyrus-Biotechnology-Enter-Collaboration-to-Create-Novel-Engineered-Therapeutic-Proteins.html

    GLOBENEWSWIRE
    08 Sep 2021
    Share Share
    Synthekine Launches with $82 Million Series A Financing to Advance Pipeline
    Synthekine Launches with $82 Million Series A Financing to Advance Pipeline

    17 Sep 2020

    // BIOSPACE

    https://www.biospace.com/article/releases/synthekine-launches-with-82-million-series-a-financing-to-advance-pipeline-of-engineered-cytokine-therapeutics-optimized-for-cancer-and-autoimmune-diseases/?s=80

    BIOSPACE
    17 Sep 2020
    Share Share